Clinical Trial Update: A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

This is an early-phase dose-escalation trial evaluating a CD19/CD22/BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CD19/CD22/BCMA CAR-T cell therapy

Snippet

Sponsor: Shanghai Cell Therapy Group Co.,Ltd | Conditions: Relapsed, Refractory | EARLY_Phase 1 | Status: RECRUITING